SUBSCRIBE
SUBSCRIBE

ITF Therapeutics

NEWS
Pictured: A scientist with pill bottles in front of FDA headquarters/Taylor Tieden for BioSpace
Policy
FDA Action Alert: Orchard, ITF, Merck and More
The FDA will close out a hectic month of March with a flurry of target action dates, including ones for lymphoma and CKD anemia treatments.
March 13, 2024
 · 
8 min read
 · 
Tristan Manalac
Pictured: Illustration of a Duchenne muscular dyst
Drug Development
ITF Gears Up for FDA Decision in Expanding DMD Market
The recently launched company shared two posters at the Muscular Dystrophy Association’s annual conference this week ahead of a March 21 PDUFA date.
March 6, 2024
 · 
5 min read
 · 
Heather McKenzie
ALS - diagnosis written on a white piece of paper. Syringe and vaccine with drugs.
FDA
ITF Secures FDA Approval for Liquid Riluzole for ALS Patients
Privately-held ITF Pharma snagged regulatory approval for Tiglutik, a liquid formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
September 7, 2018
 · 
2 min read
 · 
Alex Keown
IN THE PRESS
Press Releases
ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Givinostat Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy
August 25, 2025
 · 
10 min read
Press Releases
ITF Therapeutics LLC to Present Patient-Reported Outcome Data for DUVYZAT® (givinostat) in Duchenne Muscular Dystrophy at ISPOR 2025
May 15, 2025
 · 
7 min read
Press Releases
ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference
March 18, 2025
 · 
7 min read
Press Releases
ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts
March 5, 2025
 · 
6 min read
Press Releases
ITF Therapeutics LLC Announces Multiple Data Presentations at 2025 MDA Clinical and Scientific Conference
February 21, 2025
 · 
7 min read
Press Releases
ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer
December 4, 2024
 · 
7 min read
Press Releases
PANTHERx®Rare Partnering with ITF Therapeutics LLC for U.S. Distribution of DUVYZAT™
July 26, 2024
 · 
3 min read
Press Releases
ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy
July 25, 2024
 · 
9 min read
Pharm Country
ITF Pharma Announces Availability Of TIGLUTIK™ (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) In The United States
October 15, 2018
 · 
6 min read
FDA
ITF Pharma Announces FDA Approval Of TIGLUTIK™ (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
September 6, 2018
 · 
6 min read
JOBS